Expert Highlights Immunotherapy Success in GU Cancers – OncLive
OncLive |
Expert Highlights Immunotherapy Success in GU Cancers
OncLive The landscape of genitourinary (GU) malignancies is rapidly evolving, with promising immunotherapy breakthroughs in renal cell carcinoma (RCC) and urothelial carcinoma. The phase III randomized CheckMate-214 trial, for example, compared frontline … |
